Catalyst Pharmaceuticals IncCPRX
Price$31.49Intrinsic value$32.744% above price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $32.74median of 6 methods · middle span $21-$50based on filings through 31 Mar 2026
Market Price $31.49Price as of 14 Jul 2026
Margin of Safety +4.0%as of 14 Jul 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 8.1% (near-term consensus, capped) · years 2–5: 8.1%/yr (balance of the path).8.1% per year
Years 6–10: glide to demonstrated growth own history 26.0%, capped at 20%
Per-year rates
Yr 68.1%Yr 78.1%Yr 88.1%Yr 98.1%Yr 108.1%
8.1% → 8.1%
Years 11–20: glide to long-run rate
Per-year rates
Yr 117.6%Yr 127.1%Yr 136.6%Yr 146.1%Yr 155.6%Yr 165.1%Yr 174.5%Yr 184.0%Yr 193.5%Yr 203.0%
8.1% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)median of 2 windows (5/6y) (limited history)26.0%
Discount rate (cost of equity) 8.7%
Volatility vs market (adjusted beta)0.83

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetCatalyst Pharmaceuticals IncCPRXHealthcare
Valuation
P/E18.2×
P/S6.5×
P/B4.0×
EV / Revenue5.2×
EV / EBITDA10.1×
Profitability
Gross margin85.2%
Operating margin43.8%
Net margin37.1%
FCF margin34.9%
Returns
ROE21.9%
ROA19.3%
ROIC86.2%
Growth
Revenue growth (YoY)21.4%
5-yr fwd EPS growth—
Financial strength
Debt / Equity0.00×
Current ratio7.10×
Altman Z-Score19.9
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.